CN115461079A - 用于治疗肾癌的联用药物 - Google Patents

用于治疗肾癌的联用药物 Download PDF

Info

Publication number
CN115461079A
CN115461079A CN202180030917.4A CN202180030917A CN115461079A CN 115461079 A CN115461079 A CN 115461079A CN 202180030917 A CN202180030917 A CN 202180030917A CN 115461079 A CN115461079 A CN 115461079A
Authority
CN
China
Prior art keywords
seq
antibody
pharmaceutical composition
amino acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180030917.4A
Other languages
English (en)
Inventor
杨安琪
张喜全
王训强
于鼎
李琳
汪荣亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN115461079A publication Critical patent/CN115461079A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明属于生物医药领域，公开了一种用于治疗肾癌的联用药物，其包括抗PD‑L1抗体和安罗替尼或其药学上可接受的盐。本发明还提供了该联用药物在制备用于治疗肾癌的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN202180030917.4A 2020-04-30 2021-04-30 用于治疗肾癌的联用药物 Pending CN115461079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010365735 2020-04-30
CN202010365735X 2020-04-30
PCT/CN2021/091592 WO2021219138A1 (zh) 2020-04-30 2021-04-30 用于治疗肾癌的联用药物

Publications (1)

Publication Number Publication Date
CN115461079A true CN115461079A (zh) 2022-12-09

Family

ID=78374080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030917.4A Pending CN115461079A (zh) 2020-04-30 2021-04-30 用于治疗肾癌的联用药物

Country Status (6)

Country Link
US (1) US20230227556A1 (zh)
EP (1) EP4144371A4 (zh)
CN (1) CN115461079A (zh)
AU (1) AU2021262368A1 (zh)
CA (1) CA3181598A1 (zh)
WO (1) WO2021219138A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023160517A1 (zh) * 2022-02-22 2023-08-31 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CA2989586A1 (en) * 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
ES2953595T3 (es) * 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CA3108795A1 (en) * 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
CA3116324A1 (en) * 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer

Also Published As

Publication number Publication date
AU2021262368A1 (en) 2022-12-15
WO2021219138A1 (zh) 2021-11-04
EP4144371A1 (en) 2023-03-08
CA3181598A1 (en) 2021-11-04
EP4144371A4 (en) 2024-05-22
US20230227556A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN113347996B (zh) 治疗肿瘤的联用药物组合物
CN113613674A (zh) 治疗小细胞肺癌的联用药物组合物
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
CN113018429A (zh) 治疗卵巢癌的药物组合
CN115461079A (zh) 用于治疗肾癌的联用药物
WO2022002153A1 (zh) 用于治疗肿瘤的药物
CN118201963A (zh) 用于治疗非小细胞肺癌的药物组合
CN116036265A (zh) 用于癌症的联用药物
CN116209443A (zh) 治疗小细胞肺癌的药物组合
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
CN117642181A (zh) 用于治疗食管癌的药物组合
WO2022033585A1 (zh) 用于治疗软组织肉瘤的联用药物
CN116173198A (zh) 用于肝癌术后辅助治疗的联用药物
CN117597146A (zh) 用于治疗胃癌和/或食管胃结合部癌的联用药物
CN116510005A (zh) 治疗肿瘤的联用药物
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083393

Country of ref document: HK